Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abenol

Property	Description
Active Ingredient	Paracetamol (Acetaminophen)
Form	Oral tablet, liquid solution
Pharmacological Class	Aniline Analgesic, Antipyretic
Common Use	Symptomatic relief of pain and fever
Origin	Synthetic

Abenol: What Is This Medicine?

Abenol is a widely used over-the-counter medicine recognized for its primary role as a reliable analgesic (pain reliever) and antipyretic (fever reducer). The medication is typically available for oral administration in both tablet and liquid forms.

Its core identity is the single active ingredient, which has the international nonproprietary name (INN) of Paracetamol (also known as Acetaminophen). Paracetamol is recognized on established lists of essential medicines, which confirms its role in fundamental healthcare systems globally.

What Type of Drug Is Abenol and How Is It Classified?

Abenol belongs to the pharmacological group known as aniline analgesics and is a synthetic compound. This classification is significant because, unlike Nonsteroidal Anti-inflammatory Drugs (NSAIDs), it is clinically recognized for minimal anti-inflammatory activity.

Paracetamol's pain-relief properties stem from actions primarily within the central nervous system, influencing pain pathways and thermoregulation. This specific property makes Abenol a frequent choice for patients who require relief without the peripheral effects associated with other pain relievers.

What Is Abenol Generally Used For?

The general therapeutic goal of Abenol is to achieve reliable symptomatic relief from discomfort and fever. It is commonly used to manage the aches, pains, and elevated temperatures associated with minor ailments, such as headaches, muscle aches, and the common cold. The medication serves to improve patient comfort by managing these symptoms without treating the underlying cause of the condition.

Regulatory References

What side effects are possible with Abenol?

Abenol (Paracetamol/Acetaminophen) is associated with an official safety profile that primarily focuses on the potential for hepatotoxicity, or liver damage, which is the most critical adverse event listed in regulatory documentation. This risk is recognized as dose-related, necessitating the strict regulatory limitation against exceeding the maximum recommended daily intake and avoiding its concurrent use with any other products containing the same active ingredient.

Regulatory authorities classify other potential effects by the physiological system involved. Serious adverse reactions, though very rare, are documented and include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), and blood dyscrasias, such as agranulocytosis, which fall under the Immune system and Blood and lymphatic system disorders, respectively.

Safety Considerations for Specific Populations

Official labeling includes specific safety considerations for patient populations with pre-existing conditions:

Population Group	Regulatory Safety Note
Severe Hepatic Impairment	Abenol is formally contraindicated due to the high risk of liver toxicity.
Chronic Alcohol Use	A heightened risk of hepatotoxicity is explicitly documented for individuals with chronic excessive alcohol consumption or non-cirrhotic alcoholic liver disease.
Severe Renal Impairment	Caution is required, and increased intervals between doses may be necessary.

The label also notes that prolonged, regular, high-dose use may be associated with an enhanced anticoagulant effect of certain medicines (like warfarin) and, less commonly, the risk of renal damage (analgesic nephropathy). These factors underscore how official safety documents establish the medicine's risk framework.

Overdose and Emergency Response

Abenol overdose is formally associated with potential severe, life-threatening outcomes, primarily involving the hepatic system. Initial manifestations within the first 24 hours post-ingestion are often non-specific, including documented symptoms such as nausea, vomiting, pallor, anorexia, and diaphoresis. The absence of significant early discomfort does not reflect the severity of the ingestion, as toxicity may progress to severe hepatic necrosis and fulminant liver failure, resulting in documented complications like hepatic encephalopathy, metabolic acidosis, and coagulopathy.

Government regulatory authorities uniformly mandate that immediate medical attention must be sought in all cases of suspected overdose, even if the patient appears well. This action is critical because the specific antidote, N-acetylcysteine (NAC), is documented for use in management and is most effective when administered promptly. Hospital monitoring is required, including the measurement of serum paracetamol concentrations and serial assessment of liver function tests (LFTs) to guide treatment.

The risk of severe toxicity is noted to be greater in specific populations, including those with pre-existing hepatic impairment, chronic malnutrition, or chronic alcoholism. This regulatory focus on delayed, severe organ damage necessitates that any potential overdose situation is treated as a medical emergency requiring contact with emergency services.

Therapeutic Uses of Abenol

The therapeutic relevance of Abenol (Paracetamol/Acetaminophen) as a non-opioid analgesic and antipyretic is established. It is primarily used to help manage common forms of mild-to-moderate pain and fever.

Abenol is commonly used to help manage symptoms related to physical discomfort, which may include manifestations such as headaches, backaches, muscular discomfort, minor pain from osteoarthritis, toothache, and menstrual cramps. It is also applied across domains where additional symptomatic support is needed during acute illness, specifically to manage fever (elevated body temperature) associated with colds, flu, and post-immunization reactions. This medication may assist with maintaining functional stability and supports general well-being during symptomatic phases. Abenol is considered relevant in situations where patients require symptomatic support, including certain groups like pediatric, pregnant, and breastfeeding individuals.

Quick Fact: Supportive Management of Acute Discomfort
Abenol is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, and may be applied in scenarios where additional management of discomfort is required.

Regulatory References

NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Abenol — Official Regulatory Information

This section outlines the official eligibility and non-eligibility criteria for Abenol, based strictly on governmental regulatory documents.

Populations That Must Not Use Abenol (Contraindications)

Abenol (acetaminophen) is contraindicated and must not be used by individuals who meet any of the following criteria:

Patients with known hypersensitivity or allergy to acetaminophen or any other component in the formulation.
Patients with severe hepatic impairment or severe active liver disease.

Populations Requiring Special Consideration

Use of Abenol requires caution or a dosage adjustment for the following populations, due to increased risk of toxicity or altered clearance:

Patients with non-severe hepatic impairment.
Patients with severe renal impairment (creatinine clearance leq 30 mL/min).
Individuals with a history of chronic alcohol abuse or chronic malnutrition.
Patients with severe hypovolemia.

Age-Related Eligibility

The safety and effectiveness of the intravenous formulation for treating acute pain have not been established in pediatric patients younger than 2 years of age.

Important Restriction: Patients must not exceed the maximum total recommended daily dosage and should not take concurrently with any other product containing acetaminophen.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Abenol (acetaminophen) is associated with several documented drug and product interactions that require strict adherence to regulatory constraints.

Contraindicated Combinations

Abenol must not be taken with any other product containing acetaminophen, whether prescription or over-the-counter. This restriction is critical to avoid exceeding the maximum daily dose and to prevent the risk of severe, potentially fatal liver injury. Additionally, avoiding the consumption of alcohol (ethanol) is necessary, as it significantly increases the risk of serious hepatotoxicity.

Clinically Significant Interactions

Coadministration with oral anticoagulants, such as warfarin, may increase their anticoagulant effect, requiring dose adjustment and close monitoring of coagulation indices by a healthcare professional.

Medicines that induce hepatic enzymes, including antiepileptics like carbamazepine and phenytoin, and the antibiotic rifampin, can accelerate the metabolism of Abenol, potentially reducing its effectiveness. Conversely, some medicines, such as probenecid, may increase Abenol's concentration in the body.

The regulatory profile also lists cholestyramine and isoniazid as interacting medicines, and advises caution when co-administering with other drugs known to cause methemoglobinemia. Patients with a history of consuming three or more alcoholic drinks per day require special consideration when being evaluated for Abenol therapy.

Mechanism of Action

Abenol's mechanism of action is primarily localized to the Central Nervous System (CNS), involving modulation of thermoregulation and nociception. The initial action is the functional inhibition of Cyclooxygenase (COX) enzymes within the brain and spinal cord.

Central Modulation of Key Signaling Enzymes

By blocking COX activity, Abenol prevents the synthesis of Prostaglandin E2 ( PGE2). This inhibition in the hypothalamus interrupts the cascade that results in the resetting of the hypothalamic thermoregulatory set-point.

Indirect Neural Receptor Modulation

Beyond enzyme inhibition, the drug's metabolite, AM404, engages other neural systems, including the endocannabinoid system and TRPV1 receptors. This interaction modulates nociceptive signaling by activating descending pain pathways and reducing the sensitivity of neurons that transmit input in the spinal cord, leading to attenuation of nociceptive signal transmission.

Mechanistic Limitations from Peripheral Chemistry

A key constraint is that the drug's ability to inhibit COX is effectively neutralized at sites of intense peripheral inflammation because the high local levels of peroxides functionally constrain the molecular interaction. This limits the drug's ability to interfere with the inflammatory cascade, which results in the absence of significant peripheral anti-inflammatory activity.

Dosage and Administration Information

Abenol (Paracetamol/Acetaminophen) is utilized in clinical practice through standard administration methods and dosing principles. The medicine is utilized via the oral route in various forms, including immediate-release and extended-release tablets, and via intravenous (IV) infusion in hospital settings.

For adults weighing 50 kg or more, the standard single dose for oral or IV administration ranges from 325 mg up to 1,000 mg. The administration schedule involves maintaining a minimum interval of 4 hours between doses. This interval is established to ensure adherence to the critical dosing limit: the total cumulative intake from all formulations (oral and IV) must not exceed 4,000 mg in any 24-hour period.

Procedural guidelines stipulate that the medicine may be administered with or without food. However, specific formulations require careful handling; for example, extended-release tablets must not be crushed, cut, or chewed.

Dosing is adjusted for specific populations based on established guidance. Adults with severe renal impairment are specified to prolong the interval between doses to 6 to 8 hours. Furthermore, individuals weighing less than 50 kg utilize weight-based dosing with a lower maximum daily total. The duration of use is designated for short-term symptomatic management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Abenol (Paracetamol/Acetaminophen)

Evidence for Symptomatic Relief of Acute Pain

Abenol was studied for its use in contexts involving various types of short-term, acute discomfort using a large body of evidence, primarily consisting of short-term Randomized Controlled Trials (RCTs) and meta-analyses. Research examined outcomes related to physical discomfort by consistently measured patient-reported changes in pain intensity using standardized rating scales and tracked the need for additional pain medication. Studies conducted during periods of increased symptom activity reported that the findings describe patterns observed in the measured patient-reported outcomes in the hours immediately following a single dose. Follow-up durations were limited, meaning that evidence provides limited information for long-term outcomes or for chronic pain management.

Evidence for Fever Reduction (Antipyresis)

Abenol was evaluated in studies examining its application in the context of temporary physiological imbalance, specifically elevated body temperature. This evidence base is extensive, particularly in pediatric populations, and consists of RCTs and comparative trials. Research monitored outcomes related to systemic or functional imbalance by measuring the degree of body temperature reduction (Delta T) and the time taken for the fever to resolve. The studies reported how symptoms evolved in the observed populations, indicating patterns in measured body temperature when compared to baseline during the defined study period. What remains uncertain is the influence of reducing fever on the overall course of the underlying illness; this aspect is not fully established by the existing research.

Evidence for Pain Associated with Chronic Conditions

This area of research explores the use of Abenol in conditions where symptoms may vary in intensity over longer durations.

Research for Osteoarthritis

Abenol was evaluated in research contexts involving conditions marked by functional limitations, specifically osteoarthritis of the knee and hip, using RCTs and meta-analyses. Findings were mixed; research exploring short-term symptom changes reported that observed changes in pain scores were generally modest across the populations studied. Systematic reviews suggest that evidence quality varies across studies.

Research for Acute Low Back Pain

For adults experiencing acute, non-specific low back pain, Abenol was evaluated in high-quality RCTs and systematic reviews. Studies monitored responses over defined time intervals and consistently reported that the change in pain intensity and functional status was generally similar when comparing the medicine to a placebo.

Evidence in Specific Patient Populations

For use during pregnancy, evidence is strictly limited to Observational Studies because RCTs are not conducted in this group. Data are still emerging and certainty remains low because the findings were mixed, with some studies showing an association, but others reported that when researchers account for the reason the medicine was taken (the underlying fever or pain), the association was observed to weaken. This reliance on observational data prevents any causal conclusions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Abenol (FAQ)

Q: How does Abenol differ from other common medicines for the same purpose?

A: Abenol (paracetamol/acetaminophen) is officially classified as an aniline analgesic. The classification indicates that the medicine's action is primarily concentrated in the Central Nervous System to relieve pain. Official documents describe the compound as having minimal anti-inflammatory activity. This characteristic provides a point of distinction when compared to non-steroidal anti-inflammatory drugs (NSAIDs).

Q: What are the most common side effects reported for Abenol?

A: Official product information notes that, in addition to serious risks, the common adverse effects reported are generally mild. These can include transient nausea, vomiting, and general stomach discomfort. Adhering to the maximum recommended daily dose is essential for managing the rare, but severe, risk of liver toxicity.

Q: Can people under the age of 18 generally use Abenol?

A: Studies indicate that Abenol is widely used across pediatric and adolescent populations. However, the appropriate amount administered is calculated based strictly on the child's weight or age. Adherence to these specific instructions is important for proper dosing, as outlined in official guidelines.

Q: How long does it usually take for Abenol to start having an effect?

A: According to official product information, the onset of relief for pain or fever may occur within 15 to 30 minutes following oral ingestion. This timeframe is based on the general pharmacokinetic profile described in regulatory documents.

Q: How long does the effect of a single dose of Abenol last in the body?

A: Official regulatory sources suggest that the pain-relieving effects of a single dose of Abenol typically last for about 4 to 6 hours. This duration supports the regulatory requirement to wait a minimum of 4 hours before administering the next dose.

Q: Does Abenol have a risk of misuse or dependency?

A: Abenol is classified as a non-narcotic and is not generally considered to be an addictive substance. Safety information highlights the potential for severe risk of liver injury associated with misuse of the medication by exceeding the maximum recommended daily amount.

Q: Why is Abenol only available with a prescription?

A: Official product information indicates that Abenol, in its single-ingredient form (acetaminophen/paracetamol), is widely available as an over-the-counter medicine. This classification means that a prescription is generally not necessary to purchase the single-ingredient product.

Q: Do I need any special monitoring tests while on Abenol?

A: Regulatory guidelines do not typically require routine clinical monitoring for short-term use at the recommended doses. However, in specific populations, such as those with underlying liver disease or individuals on prolonged treatment, official guidelines suggest a healthcare professional may recommend periodic monitoring of liver function.

Q: How often are users reported to feel nausea or stomach upset with Abenol?

A: Nausea, vomiting, and abdominal pain are noted as adverse effects that have been reported from use of Abenol, and are noted in regulatory documentation.

Q: Can I use Abenol while taking multivitamin supplements?

A: Official regulatory guidance advises that patients should inform a healthcare professional about all vitamins and supplements they are taking. While common multivitamins are not typically listed as interacting with the medicine, regulatory guidance stresses that informing a healthcare professional about all supplements taken is important.

Q: Does Abenol interact with herbal or natural supplements, such as St. John's Wort?

A: Official documentation and related research advise caution with certain herbal supplements, such as St. John’s Wort. This is because some supplements are known to influence liver enzymes, which can potentially increase the risk of liver injury associated with Abenol.

Q: Can older adults generally be prescribed Abenol?

A: Official documents suggest that the processing and metabolism of Abenol are generally not significantly altered in elderly individuals. Therefore, a specific dose adjustment is not typically required solely based on a person’s age in this population.

Q: Is Abenol recommended for use while breastfeeding?

A: Based on studies and official drug databases, Abenol is typically found to be compatible with breastfeeding when used at standard therapeutic amounts. This is because the amount of the active ingredient that passes into breast milk is considered very small.

Q: What is the typical timeframe before the full benefits of Abenol are noticed?

A: Abenol is officially designated for short-term management of symptoms. If the pain or fever persists, worsens, or lasts beyond a few days, regulatory guidance advises seeking guidance from a healthcare professional.

Q: What are the general expectations if someone stops taking Abenol suddenly?

A: Because Abenol is a non-narcotic medicine, it is not generally associated with physical dependence. Stopping the use of the single-ingredient formulation abruptly at therapeutic doses is not expected to cause withdrawal symptoms.

Q: Is Abenol classified as a controlled substance by official bodies?

A: Official government classification lists Abenol (acetaminophen/paracetamol) as a non-narcotic analgesic. It is not designated as a scheduled controlled substance under major regulatory frameworks, such as the U.S. Controlled Substances Act.

Q: Where can I find the official government documents about Abenol research evidence?

A: To review the official regulatory documentation, including the full Prescribing Information and safety profile, you can access government websites. These sites include the U.S. FDA, the NIH DailyMed, and the European Medicines Agency ( EMA), where the documents are publically available.

Q: Is Abenol available as a generic medicine?

A: Yes, the active ingredient in Abenol, which is Paracetamol or Acetaminophen, is a well-established compound. As a result, it is widely available as a generic medicine.

Q: What if I forget to take a scheduled dose of Abenol?

A: Official product information suggests that if a dose is missed, it can be taken as soon as the lapse is remembered. However, it is essential to ensure that this action does not result in exceeding the maximum total recommended daily dose within a 24-hour window.

How should Abenol be stored and disposed of?

How to Store and Dispose of Abenol?

Abenol (acetaminophen) must be stored and handled according to regulatory requirements to maintain product stability and ensure safety.

Official Storage Conditions

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Protection	Protect from excessive heat, moisture, and light. Do not freeze liquid forms.
Container	Keep in the original container, tightly closed, with the safety seal intact.
Child Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Abenol should be disposed of via a community drug take-back program. If unavailable, the product must be mixed with an unappealing substance (like dirt or used coffee grounds) and placed into a sealed container before disposal in household trash. Do not flush Abenol down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.